OncoDNA Gathers Huge Support for Its Precision Cancer Medicine
OncoDNA, a company using next-generation sequencing to match patients with a personalized cancer treatment has now teamed up with the Strasbourg University Hospital, France, and the Oncology Center of Bydgoszcz, Poland, in the advancement of precision medicine for cancer.
The Belgian biotech’s international project, Moncodaneum aims at connecting major oncology centers worldwide through the big data platform OncoKDM. It is a tool that can gather data from all sorts of tests — NGS, RT-qPCR, immunohistochemistry, etc. — of any cancer type, and put together a comprehensive report for the patient directly from the raw data. The aim is to help physicians save valuable time and find the best treatment for each patient.
OncoDNA uses next-generation sequencing to analyze major DNA mutations in cancer and match the patient with a personalized treatment option. The coolest part is that the whole process can be controlled via a mobile app with a pretty neat design. Early last year, the company also launched OncoTRACE, the first non-invasive personalized test to monitor tumor progression.
Pilot projects using OncoKDM are already underway with SOLTI, a Spanish non-profit organization running clinical trials in breast cancer. OncoDNA is already negotiating the incorporation of oncology centers from Norway
, the Netherlands, Spain and Belgium to the project, which aims to connect 50 major cancer centers across 30 countries.
